CheCUP
A phase II, open-label, non-randomized, multi-center study evaluating the efficacy and safety of nivolumab plus ipilimumab in patients with cancer of unknown primary site who are relapsed after or refractory to platinum-based chemotherapy
II
Status: Studie beendet
Zeitraum
2019
2021
Zentren
11
9
Keine Zentren gesucht
Patienten
194
20
14.04.2022
Identifier
AIO-CUP-0119/ass
Kontakt
Leitung
Prof. Dr. Alwin Krämer
Ansprechpartner*in
Prof. Dr. Alwin Krämer
Telefon +49 6221 421440